Exploiting the DNA-damage repair defect of BRCA1-deficient pancreatic cancer cells in drug therapy

In this study we show that BRCA1-deficient murine pancreatic carcinoma cells are sensitive to DNA damaging drugs like Mitomycin C and Cisplatin.

Preview

Rights

Use and reproduction:

No license. The provisions of the German Copyright Act (UrhG) apply.

Please note that individual components of the publication may be subject to other licensing or copyright conditions.

Cite

Citation style:
Could not load citation form.